Beyond ReWalk: The Public Companies Competing for the Future of Exoskeletons and Neurorehabilitation — $LFWD $MYO $CHRN $APLD

1. What exactly is the investable sector?

“Exoskeleton” is a powerful word, but it covers products with very different purposes, customers, regulatory requirements and business models. A useful public-equity map must separate them.

Personal mobility exoskeletons

These are wearable powered lower-limb systems intended to allow selected people with paralysis—primarily spinal cord injury—to stand and walk outside a traditional therapy session. The closest listed-product comparison is between Lifeward’s ReWalk 7 and the Indego Personal platform now operated by the legacy Ekso business inside ChronoScale.

Personal exoskeletons are high-value medical devices. They require evaluation, fitting, training, documentation, reimbursement work and ongoing service. Their economic opportunity is attractive on a per-unit basis, but the eligible patient funnel is narrow. Not every person with spinal cord injury has the upper-body strength, bone health, joint mobility, cognition, body dimensions or desire required to use one safely.

Clinical rehabilitation exoskeletons

Clinical systems are used by trained therapists in hospitals and rehabilitation centers. They can support repetitive gait training after stroke, acquired brain injury, spinal cord injury or multiple sclerosis. EksoNR, Ekso Indego Therapy, ReWalk Rehabilitation, CYBERDYNE HAL and Angel Legs occupy parts of this market.

The customer is an institution rather than an individual. The commercial decision depends on capital budgets, therapist productivity, clinical evidence, patient throughput, training requirements, maintenance, service contracts and whether the system can be integrated into a repeatable rehabilitation program.

Powered upper-limb orthoses and robots

Myomo’s MyoPro is a personal powered arm brace that senses residual muscle signals and assists elbow, wrist and hand movement. DIH’s Armeo family is mainly designed for institution-based arm and hand therapy. Lifeward’s acquired Skelable assets aim to create a future upper-body exoskeleton initially focused on post-stroke impairment.

This segment may ultimately reach more patients than personal lower-body exoskeletons because upper-limb weakness after stroke and neurological injury is common and directly affects eating, dressing, hygiene, work and independent living. However, the word “upper-body exoskeleton” can describe anything from a rehabilitation robot to an industrial shoulder-support device. Product purpose matters.

Robotic rehabilitation systems that are not wearable exoskeletons

Hocoma’s Lokomat, Armeo and Erigo systems, Motek’s C-Mill, RYSEN and CAREN, AlterG anti-gravity treadmills, SafeGait and BalanceTutor all compete for rehabilitation budgets. They are not all exoskeletons, but they compete with exoskeleton companies for the same clinical objective: delivering more intensive, measurable, repeatable movement therapy.

Industrial, military and augmentation exoskeletons

Industrial devices support workers during overhead tasks, lifting or prolonged physical activity. Ekso EVO and Angel Robotics’ industrial products belong here. Military systems seek to increase endurance, load carriage or operational capability. These markets are adjacent to medical robotics but have different regulatory and purchasing dynamics. They should be analyzed as optionality, not automatically combined with medical revenue.

2. Who were the pioneers?

The sector has no single founder. Different pioneers solved different parts of the problem: powered assistance, human-machine control, clinical rehabilitation, personal mobility, reimbursement and commercialization.

The most important distinction: first to invent is not the same as first to commercialize

ReWalk was not the first powered exoskeleton concept, and it was not the first robot used in rehabilitation. Its pioneering status comes from a more specific achievement: it moved a powered lower-limb exoskeleton from engineering and supervised rehabilitation into FDA-authorized personal use.

Hocoma’s pioneering status is different. Lokomat helped create the institutional market for robotic gait therapy. CYBERDYNE pioneered bioelectrical intent control and the idea of “cybernics,” integrating humans, robots and information systems. Berkeley Bionics and Ekso helped advance untethered wearable exoskeleton engineering and broadened clinical indications. Myomo pioneered a commercially reimbursed, personalized, user-controlled powered arm orthosis.

3. Listed, indirectly listed and formerly listed companies at a glance

The peer set is intentionally narrow. Large diversified companies with experimental robotics programs are excluded from the core comparison because exoskeleton exposure is immaterial to their consolidated financial results.

4. Lifeward: the personal-use pioneer trying to become a platform

For the complete company history, readers can consult the Merlintrader Lifeward Stock Hub. In the competitive map, Lifeward matters because ReWalk established the benchmark against which personal lower-limb exoskeletons are still judged.

Amit Goffer founded the company after becoming quadriplegic in a 1997 accident. The early ReWalk prototypes combined powered hip and knee joints, sensors, software, batteries and user-controlled commands. The user shifts the upper body and manages balance with crutches while the device produces powered steps.

The 2014 FDA de novo authorization was the company’s historic achievement. It created a Class II regulatory category for powered exoskeletons and permitted personal use by qualified individuals with spinal cord injury under specified conditions. Later generations added improved fitting, software, cloud connectivity and U.S. authorization for stairs and curbs. ReWalk 7 received FDA clearance in 2025.

The company’s commercial problem was that regulatory leadership arrived long before broad reimbursement. Personal exoskeleton users are highly selected, training is extensive and insurers historically treated the devices as experimental or non-covered. The Department of Veterans Affairs, German statutory insurers and eventually Medicare helped establish structured pathways.

CMS’s decision to place personal exoskeletons within the Medicare brace benefit and establish a national payment benchmark around $91,032 changed the commercial environment. It did not remove the difficult parts of the funnel: physician documentation, candidate eligibility, training, prior authorization, claim processing and cash collection.

Lifeward’s broader portfolio

The 2023 acquisition of AlterG diversified the company into anti-gravity treadmills and a larger institutional installed base. ReStore added a soft exosuit for post-stroke gait rehabilitation. MyoCycle supplied an adjacent FES cycling product. The company then acquired Skelable upper-body exoskeleton assets and a Protein Oral Delivery platform through its 2026 Oramed-related transaction.

This diversification creates more opportunities but makes Lifeward difficult to classify. It is now part personal exoskeleton company, part rehabilitation-equipment supplier, part wearable-robotics developer and part clinical-stage drug-delivery platform.

Financial and capital-structure reality

Lifeward generated approximately $22.0 million of revenue in 2025, down from approximately $25.7 million in 2024. First-quarter 2026 revenue was approximately $3.9 million as lower AlterG shipments more than offset higher ReWalk revenue. The company ended March 2026 with approximately $11.4 million in cash after the Oratech transaction and financing, but it remained loss-making and exposed to working-capital pressure.

The risk for common shareholders is not limited to operational execution. Convertible notes, pre-funded warrants, conventional warrants and revenue-sharing obligations make the fully diluted capital structure materially more complex than the basic share count. The July 2026 senior secured convertible-note financing added more capital and more potential dilution.

Competitive position

5. Myomo: the most useful commercial model for upper-body robotics

Myomo is not a direct competitor to ReWalk’s lower-limb exoskeleton. It is, however, the most important public-company comparison for Lifeward’s planned upper-body program.

MyoPro is a lightweight, non-invasive powered arm orthosis. Sensors detect the user’s residual neuromuscular signals, and motors assist movement of the elbow, wrist and hand. The product is designed for people with weakness or paralysis following stroke, brachial plexus injury, spinal cord injury and other neurological conditions.

The technology originated from work at MIT and Harvard Medical School and was developed into a personalized commercial system. This makes Myomo a pioneer in human-machine control for the upper limb. It does not merely move a patient’s arm through a pre-programmed therapeutic trajectory. It attempts to amplify the user’s own movement intention.

The commercial engine

Myomo has built a patient funnel combining advertising, referrals, clinical screening, insurance authorization, fitting through orthotics and prosthetics channels, manufacturing and delivery. This model is operationally demanding, but it has reached a scale that remains unusual in medical robotics.

The company reported full-year 2025 revenue of $40.9 million and fourth-quarter revenue of $11.4 million. It received a record 241 authorizations and orders in the fourth quarter and entered 2026 with guidance of $43 million to $46 million. In the first quarter of 2026, revenue reached $10.1 million, orders increased 12% year over year and 49% of revenue came from recurring patient sources.

Myomo has increasingly emphasized referrals and recurring patient sources rather than depending only on paid consumer leads. That matters because digital lead generation can be expensive and low quality. A referral from a clinician, existing patient, O&P practice or insurer may produce a higher probability of medical qualification and reimbursement.

Why Myomo matters to Lifeward

Lifeward’s upper-body device is still in development. Myomo already demonstrates the infrastructure required to turn an upper-limb robot into revenue:

• identify people with enough residual muscle activity to benefit;
• obtain clinical documentation and a prescription;
• fit a customized orthosis;
• submit a high-value reimbursement claim;
• manage denials and appeals;
• train the user and monitor engagement;
• build relationships with O&P clinics and rehabilitation centers.

A Lifeward upper-body launch may eventually compete with MyoPro, but the exact overlap depends on intended use. A clinic-based rehabilitation exoskeleton would compete more directly with DIH’s Armeo products. A personal take-home assistive orthosis would move much closer to Myomo’s model.

Competitive position

6. DIH Holding US: the institutional rehabilitation platform

DIH is the broadest listed rehabilitation-technology company in the peer group. Its value lies less in one wearable exoskeleton and more in the portfolio created by combining pioneering brands.

Motek Medical was founded in 1994 and developed advanced movement-analysis, virtual-reality and instrumented treadmill systems. Hocoma was founded in 2000 and became one of the earliest commercial leaders in robotic rehabilitation. DIH itself began in 2007, initially as a medical-device distributor in Asia, and later brought Hocoma, Motek and additional rehabilitation assets under one platform.

Hocoma: the clinical pioneer

Lokomat is a robotic gait-training system that combines a treadmill, body-weight support and robotic leg guidance. It helped establish the concept that a patient could perform large numbers of repeatable gait cycles while therapists adjusted assistance and measured performance.

Hocoma later expanded across the rehabilitation continuum:

• Erigo for early mobilization and verticalization;
• Lokomat for robot-assisted gait training;
• Andago for mobile body-weight-supported walking;
• Armeo Power and Armeo Spring for arm and hand rehabilitation;
• HocoNet and data platforms for connected therapy management.

DIH reports that the 1,000th Lokomat was installed in 2020. That milestone demonstrates a scale of institutional adoption that personal exoskeleton companies have not yet achieved.

Motek: research, movement and virtual reality

Motek products such as C-Mill, RYSEN, GRAIL and CAREN combine treadmills, force plates, motion capture, virtual environments and body-weight support. These are large institutional systems used in rehabilitation and human-movement research.

They compete indirectly with exoskeletons because a clinic deciding how to improve gait therapy may allocate its budget toward a Lokomat, C-Mill or RYSEN instead of a wearable robot. The products are not substitutes in every clinical scenario, but they compete for capital, floor space, therapist training and evidence-based program development.

Why DIH is structurally different

DIH sells primarily to hospitals, clinics, research centers and institutional rehabilitation programs. Revenue is therefore influenced by capital-equipment cycles, distributor performance, public budgets and large project timing. The company also has service, training and software opportunities that can generate more recurring revenue than a one-time device sale.

The institutional installed base is a competitive moat, but it brings complexity. Large systems can have long sales cycles, high manufacturing costs and exposure to hospital spending constraints. DIH has also used convertible financing, making capitalization and liquidity important parts of the equity analysis.

Competitive position

7. ChronoScale and the legacy Ekso business: the closest competitor hidden inside an AI company

Ekso Bionics was historically one of the clearest public peers for Lifeward. That changed on May 5, 2026.

Applied Digital contributed its cloud-compute business to Ekso Bionics. Ekso changed its corporate name to ChronoScale and began trading under ticker CHRN. Applied Digital received approximately 138 million shares and invested another $15.75 million, resulting in ownership of approximately 97% of ChronoScale’s outstanding shares at closing. The legacy Ekso business continues as a wholly owned subsidiary.

This means the products remain relevant to the sector, but the stock is no longer a pure exoskeleton security. ChronoScale presents itself primarily as an accelerated-compute platform serving AI training, inference and high-performance computing.

Indego Personal: ReWalk’s closest direct competitor

Ekso acquired the Human Motion & Control business from Parker Hannifin in 2022, including Indego Personal and Indego Therapy. Indego originated from Vanderbilt University research and was commercialized by Parker before joining Ekso.

Indego Personal is a lightweight modular lower-limb powered orthosis for people with spinal cord injury from T3 to L5. It allows eligible users to stand and walk in home and community environments. Like ReWalk, it requires clinical evaluation, training and support. It is positioned within the same Medicare benefit and payment environment.

This is the most direct competitive pairing in the listed universe:

EksoNR and enterprise rehabilitation

EksoNR is a clinical exoskeleton cleared for use with spinal cord injury, stroke, acquired brain injury and multiple sclerosis. It allows therapists to adjust assistance and conduct high-intensity gait training. The legacy Ekso business markets clinical exoskeleton systems across the Americas, Europe, the Middle East and Africa, and Asia-Pacific; a precise current center count was not used because it was not consistently disclosed in the primary filings reviewed.

The legacy portfolio also includes Indego Therapy, the industrial Ekso EVO, BalanceTutor distribution and Nomad, a powered knee-ankle-foot orthosis that Ekso expected to begin commercializing in late 2026, subject to clinical feedback and development.

Legacy Ekso financial picture before the transaction

Ekso generated approximately $12.8 million of revenue in 2025, down from approximately $17.9 million in 2024. The company reported a 2025 net loss of approximately $11.7 million and used approximately $11.8 million of cash in operations. Cash and restricted cash fell to approximately $1.2 million at year-end before the ChronoScale transaction.

Those numbers explain why the combination with Applied Digital’s cloud business transformed the equity story. The exoskeleton operation had valuable technology and regulatory assets but lacked scale and capital. ChronoScale supplied a radically different business and ownership structure.

How to treat CHRN in a sector comparison

CHRN should be included because it owns the legacy Ekso products and therefore controls Lifeward’s most direct commercial competitor. It should not be valued as if exoskeletons drive the parent company’s revenue, strategy or stock behavior. Investors interested specifically in medical robotics must monitor whether ChronoScale invests in, partners, sells or deprioritizes the Ekso subsidiary.

8. CYBERDYNE: the bioelectrical pioneer

CYBERDYNE’s founder, University of Tsukuba professor Yoshiyuki Sankai, began developing the concepts behind HAL around the end of the 1980s. The company was founded in 2004 and later listed in Japan.

HAL stands for Hybrid Assistive Limb. Its defining concept is that the device detects faint bioelectrical signals generated when the brain sends movement commands to the muscles. The robot then assists the intended movement, while the sensory result returns to the nervous system. CYBERDYNE describes this human-machine feedback loop as part of “cybernics.”

This is different from a system that simply moves the user through a programmed trajectory. HAL’s strategic claim is that assistance based on biological intent may support motor learning and neurological recovery as part of structured treatment.

Product and treatment model

CYBERDYNE offers lower-limb HAL systems, single-joint devices and a wider ecosystem involving care support, cleaning robots, vital sensing and cybernic treatment centers. Its business has historically emphasized leasing, treatment programs and institutional deployment rather than selling a high-value personal DME device through U.S. Medicare.

HAL has received regulatory approvals in multiple regions and has been deployed through hospitals and specialized treatment centers. The company has pursued neurological indications including spinal cord injury, stroke and neuromuscular disease.

Why CYBERDYNE is a real peer—and why it is not a clean comp

CYBERDYNE is a real technological peer because it builds wearable powered systems for neurological rehabilitation. It competes for clinical validation, hospital partnerships, government support and the global reputation of being a leader in human-assist robotics.

It is not a clean valuation comparable because:

• its geographic revenue mix is centered on Japan and selected international markets;
• its treatment and leasing model differs from U.S. personal-device reimbursement;
• its product ecosystem extends beyond exoskeletons;
• its governance structure gives founder-related holdings substantial voting influence;
• Japanese accounting, disclosure and market conventions complicate direct multiple comparisons.

Pioneer status

CYBERDYNE deserves to be regarded as one of the sector’s scientific pioneers. ReWalk’s claim is strongest around personal mobility and FDA authorization. HAL’s claim is strongest around detecting biological intent and integrating wearable robotics with neurological treatment.

9. Angel Robotics: the newer Asian challenger

Angel Robotics’ official milestone history begins in 2017, and the company subsequently became listed on Korea’s KOSDAQ under code 455900. It represents a newer phase of wearable robotics in which compact hardware, integrated sensors, software, AI and data monitoring are designed together.

Its core technology attempts to recognize movement intent without requiring attached biosensors. On-device AI, motion-analysis algorithms and integrated sensors estimate what the user is trying to do and provide assistance across walking, standing, sitting and stairs. The company also generates movement-analysis reports covering gait cycles, joint angles and walking speed.

Healthcare products

Angel Legs M20 is a medical wearable robot for gait training and lower-limb rehabilitation. It provides powered assistance and customizable training modes.

Angel Suit H10 is a lighter hip-assist wearable designed to support walking and rehabilitation. The company launched the H10 in 2025.

Angel Robotics also develops products and components for industrial safety, human-performance enhancement and defense. Internalizing actuators and other key components could support cost control and product differentiation.

Competitive relevance

Angel Robotics competes more directly with clinical exoskeletons and wearable gait-assist products than with ReWalk’s U.S. Medicare funnel. Its strongest markets and regulatory position remain in Korea and Asia, although certifications in Thailand and Vietnam illustrate regional expansion.

Its significance for investors is that it demonstrates where product design is heading:

• lighter and more specialized devices;
• AI-based intent recognition;
• connected applications and movement data;
• multiple products built on shared actuators and software;
• expansion from medical rehabilitation into industrial and defense markets.

The main limitation is access. U.S. investors may find it more difficult to trade KOSDAQ securities, obtain English-language financial detail and compare Korean disclosure with SEC-reporting companies.

10. Product competition by segment

11. Reimbursement: the real competitive moat

Wearable medical robots are expensive, individualized and difficult to evaluate with conventional reimbursement frameworks. A company can have superior engineering and still fail commercially if patients cannot obtain payment.

Personal lower-limb exoskeleton reimbursement

ReWalk spent years building case-by-case coverage through the VA, German insurers, workers’ compensation and private payers. Medicare’s decision to recognize personal exoskeletons within the brace benefit established a national U.S. framework and a payment level around $91,032.

Indego Personal can pursue the same broad opportunity. The direct competition is therefore no longer only about device specifications. It is about which organization can:

• generate qualified patient leads;
• place evaluation devices near patients;
• train therapists and support persons;
• produce complete medical documentation;
• submit accurate claims;
• manage denials and appeals;
• deliver the device and collect cash efficiently.

Upper-limb reimbursement

Myomo has spent years establishing codes, coverage and payment for MyoPro. Its experience demonstrates that a high payment amount does not automatically create a high-margin business. Patient acquisition, insurance authorization, customization, fitting and delivery consume time and resources.

Lifeward’s upper-body program will need to decide whether it is primarily a therapy device sold to institutions or a personal orthosis reimbursed for home use. The commercial infrastructure and evidence package are very different.

Institutional products

Hocoma, Motek, AlterG, EksoNR, HAL and Angel products often depend on capital-equipment budgets rather than a claim for each individual patient. This can reduce claim complexity but create longer procurement cycles. Hospitals may compare the device against other equipment, software, staffing and construction priorities.

12. Financial comparison: what the reported numbers really show

Direct financial comparisons require caution. Lifeward, Myomo and the legacy Ekso business report under U.S. public-company standards, but they have different product mixes. DIH is a broader institutional platform. CYBERDYNE reports in yen and operates a different treatment model. Angel Robotics reports in won and remains earlier in its international commercialization.

Why Myomo currently looks different

Among the currently active U.S.-listed names in this narrow group, Myomo provides the clearest stand-alone disclosure of a scaled powered-orthosis commercial funnel. Its reported metrics include pipeline additions, authorizations, orders, deliveries, recurring patient sources and cost per pipeline add. That is a statement about disclosure quality and business focus—not a claim that Myomo is the largest rehabilitation-technology company by revenue.

That does not make the company low risk. It does make it a useful benchmark for what commercial maturation can look like in a reimbursed powered-orthosis market.

Why apparent low valuations can be deceptive

Several sector companies have used reverse splits, warrants, convertible debt, pre-funded warrants and other financing structures. A screen-quoted market capitalization may understate the economic claims on the business. Investors should build a fully diluted capitalization table before comparing enterprise value to revenue.

This is especially important for Lifeward, DIH and the former standalone Ekso structure. A low share count after a reverse split does not reverse historical dilution. A high conversion price does not eliminate note risk. “Anti-dilutive” accounting treatment during a loss period does not mean warrants and convertibles are economically irrelevant.

13. Which companies are the true direct competitors?

Tier 1: direct product competition

Tier 2: direct customer-budget competition

AlterG, Lokomat, C-Mill, SafeGait, RYSEN, BalanceTutor and conventional body-weight-support systems may not perform the same function, but they compete for the same hospital or clinic budget. A rehabilitation director may choose the system that treats the widest patient population, improves therapist efficiency and generates the most billable utilization.

Tier 3: strategic and technological competition

CYBERDYNE and Angel Robotics compete for international partnerships, clinical evidence, engineering talent and government support. Their success can influence how hospitals and regulators perceive the entire category.

Not true peers

Toyota, Honda, Hyundai, Panasonic, Samsung, Lockheed Martin and other large companies have developed or supported robotics and exoskeleton projects. They are relevant to the industrial history and competitive threat, but exoskeletons are too small relative to their consolidated businesses to use them as meaningful public-equity comparables.

14. The private companies that still shape the market

An article limited to public stocks would miss several important competitors. These businesses cannot be purchased directly in the public market, but they influence technology, pricing and acquisition strategy.

Wandercraft

Wandercraft develops self-balancing robotic walking systems. Self-balancing is strategically important because reliance on crutches limits personal exoskeleton adoption. The engineering challenge is to add balance without making the product prohibitively heavy, expensive or power intensive.

Ottobock

Ottobock is a major global prosthetics and orthotics company with rehabilitation and exoskeleton activities. Its distribution, clinical relationships and fitting infrastructure make it an important strategic player. Myomo’s availability through Ottobock Care clinics illustrates how larger O&P networks can accelerate access.

Tyromotion and Fourier Intelligence

These companies offer broad rehabilitation-robotics portfolios spanning gait, balance, arm and hand therapy. They compete directly with DIH and can influence pricing and hospital procurement.

B-Temia, Trexo Robotics and emerging developers

Smaller developers are working on mobility assistance, pediatric gait training and lighter wearable systems. Many will remain private, seek partnerships or become acquisition targets rather than independent public companies.

15. Why the sector has remained commercially difficult

Clinical value is not the same as daily utility

A patient can experience meaningful psychological and physical benefits from standing or walking while still relying primarily on a wheelchair. Personal exoskeletons are slower, require preparation and may be unsuitable for many environments. The product must create enough incremental utility to justify extensive training and a high cost.

The eligible market is smaller than the disease population

Not every person with spinal cord injury can use ReWalk or Indego. Not every stroke survivor has the residual muscle activity or joint condition required for MyoPro. The theoretical prevalence figure is only the top of a funnel narrowed by medical eligibility, motivation, access, payer policy and training.

Training capacity limits growth

Wearable robots need trained clinicians. A region without evaluation and training centers is not a fully addressable market. Companies must invest in clinical education before revenue appears.

Manufacturing volumes remain low

Low volume keeps component and service costs high. Devices contain motors, batteries, sensors, custom frames, software and safety systems. A small company may struggle to negotiate favorable supplier terms or maintain inventory without tying up cash.

Evidence requirements keep rising

Early studies proved feasibility. The next commercial stage requires evidence of functional outcomes, safety, durability, patient adherence, healthcare utilization and economic value. Payers and hospitals increasingly want more than a compelling demonstration.

Service is part of the product

A broken consumer gadget is inconvenient. A malfunctioning exoskeleton can interrupt therapy or expose a vulnerable user to risk. Companies need responsive service, spare parts, loaner devices, software support and quality systems.

16. The next generation of competition

From rigid systems to specialized wearables

The market is moving toward lighter devices focused on a specific joint, movement or phase of rehabilitation. MyoPro targets the arm. Ekso Nomad targets knee-ankle-foot assistance. Angel Suit targets hip assistance. Lifeward’s Skelable assets target upper-body impairment.

AI and intent recognition

Artificial intelligence is most useful when it improves movement-intent detection, fitting, adaptive assistance, safety or therapist workflow. Attaching the term “AI” to a product is not a commercial advantage by itself. Investors should ask whether the algorithm reduces training time, improves outcomes or lowers cost.

Cloud connectivity and longitudinal data

Connected devices can show payers whether a patient is using the system, help clinicians track progress and allow manufacturers to predict service needs. Data may become a reimbursement asset if companies can link usage to outcomes.

Self-balancing personal mobility

Eliminating crutches could expand the eligible population and improve real-world utility. It also raises difficult engineering and regulatory questions. Balance must remain reliable across uneven ground, turns, slopes, obstacles and user errors.

Hybrid business models

Future winners may combine device sales, leasing, subscriptions, service, software, data and clinical programs. The objective is to reduce dependence on unpredictable one-time equipment revenue.

17. Catalyst map by company

18. Bull case for the sector

19. Bear case for the sector

20. Red flags to monitor across every company

21. Which stock offers the cleanest exposure?

There is no perfect public pure play.

LFWD offers the strongest direct exposure to ReWalk, but AlterG, upper-body development and oral biologics make it increasingly diversified. Its capitalization is complex.

MYO is currently the cleanest listed exposure to a scaled personal powered-orthosis model. It is focused, growing and operationally measurable, but it is upper limb rather than lower-limb exoskeleton exposure.

DIH offers the broadest institutional rehabilitation portfolio in this group, but its former Nasdaq ticker DHAI is not shown as active in the SEC’s current ticker/exchange mapping. It remains an industrial peer, not a currently tradable U.S.-listed comparison.

CHRN owns the closest ReWalk competitor through legacy Ekso, but AI compute now dominates the listed-company identity and ownership structure. APLD is relevant only as the controlling shareholder immediately after the transaction; it is not an operating medical-robotics peer.

CYBERDYNE offers historically important wearable neuro-robotics exposure, but through a Japanese treatment and technology model.

Angel Robotics offers newer Asian wearable-robotics exposure, with higher geographic and disclosure friction for U.S. investors.

22. Bottom line

The exoskeleton industry is no longer waiting for proof that a robot can help a paralyzed person stand, guide a stroke patient through gait training or assist a weakened arm. Those milestones were achieved by the pioneers. The unresolved question is whether the industry can make those capabilities routine, reimbursable and profitable.

Hocoma helped turn robotic rehabilitation into a commercial hospital category. CYBERDYNE pioneered bioelectrical human-machine interaction. ReWalk made the historic leap into FDA-authorized personal use. Berkeley Bionics and Ekso advanced clinical exoskeletons and later acquired the Indego personal platform. Myomo built one of the sector’s most developed direct-to-patient reimbursement machines for powered upper-limb orthoses. Angel Robotics represents the next generation of lighter, connected and AI-assisted wearables.

For Lifeward, the competitive landscape is both narrower and broader than it first appears. ReWalk has only one clearly comparable listed personal lower-limb rival: Indego, now hidden inside ChronoScale. But Lifeward competes with many more companies for rehabilitation budgets, clinician time, patient referrals, payer confidence and investor capital.

The pioneers proved the technology. The next winners must prove the business model.

Primary sources and further research